Lung cancer Patients' own immune cells deployed in new trial
NCT ID NCT07560111
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This phase II trial tests a new treatment for non-small cell lung cancer using immune cells taken from the patient's own tumor. The cells are grown in a lab and then infused back to attack the cancer. The study will enroll 28 adults and measure how well the treatment shrinks tumors and delays cancer growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?